Imipramine and weight gain during the treatment of recurrent depression
- PMID: 2148336
- DOI: 10.1016/0165-0327(90)90140-4
Imipramine and weight gain during the treatment of recurrent depression
Abstract
Weight change was examined in 128 depressed outpatients treated successfully with an average dose of 215 mg imipramine and then continued on that treatment regimen for 5 additional months, an average duration of over 33 weeks. More than half the patients experienced a change in weight of 5% or less and only 13.3% experienced a gain of greater than 10%. While males and females did not differ in their pattern of change during acute treatment, females experienced a greater percent change (P less than 0.06) and change in body mass index (P = 0.05) during continuation treatment. The clinical implications of these findings are discussed, especially with respect to the extreme group.
Similar articles
-
Imipramine and weight gain during the long-term treatment of recurrent depression.J Affect Disord. 1992 Sep;26(1):65-72. doi: 10.1016/0165-0327(92)90036-6. J Affect Disord. 1992. PMID: 1430670 Clinical Trial.
-
Response of depression to very high plasma levels of imipramine plus desipramine.Biol Psychiatry. 1991 Jul 1;30(1):57-62. doi: 10.1016/0006-3223(91)90070-3. Biol Psychiatry. 1991. PMID: 1892963
-
Adequate treatment with imipramine in continuation treatment.J Clin Psychiatry. 1989 Jul;50(7):250-5. J Clin Psychiatry. 1989. PMID: 2661546 Clinical Trial.
-
Relapse in recurrent unipolar depression.Am J Psychiatry. 1987 Jan;144(1):86-8. doi: 10.1176/ajp.144.1.86. Am J Psychiatry. 1987. PMID: 3799845
-
Guidelines for the long-term treatment of depression.J Clin Psychiatry. 1994 Dec;55 Suppl:61-9; discussion 70-1. J Clin Psychiatry. 1994. PMID: 7814359 Review.
Cited by
-
The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.CNS Drugs. 2010 Sep;24(9):741-53. doi: 10.2165/11533280-000000000-00000. CNS Drugs. 2010. PMID: 20806987 Review.
-
Cardiometabolic effects of psychotropic medications.Horm Mol Biol Clin Investig. 2018 Jan 10;36(1):/j/hmbci.2018.36.issue-1/hmbci-2017-0065/hmbci-2017-0065.xml. doi: 10.1515/hmbci-2017-0065. Horm Mol Biol Clin Investig. 2018. PMID: 29320364 Free PMC article. Review.
-
AGN-2979, an inhibitor of tryptophan hydroxylase activation, does not affect serotonin synthesis in Flinders Sensitive Line rats, a rat model of depression, but produces a significant effect in Flinders Resistant Line rats.Neurochem Int. 2009 Dec;55(7):529-35. doi: 10.1016/j.neuint.2009.05.008. Epub 2009 May 20. Neurochem Int. 2009. PMID: 19463878 Free PMC article.
-
Medications that cause weight gain and alternatives in Canada: a narrative review.Diabetes Metab Syndr Obes. 2018 Aug 21;11:427-438. doi: 10.2147/DMSO.S171365. eCollection 2018. Diabetes Metab Syndr Obes. 2018. PMID: 30174450 Free PMC article. Review.
-
Comparing the effects of fluoxetine and imipramine on total cholesterol, triglyceride, and weight in patients with major depression.Daru. 2013 Jan 5;21(1):4. doi: 10.1186/2008-2231-21-4. Daru. 2013. PMID: 23351476 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources